ライフサイエンスコーパス: negative symptom

1 sity, and anhedonia, as well as parent-rated negative symptoms).

2 were similar with CVR, and for positive and negative symptoms.

3 e symptoms in both study groups, but not for negative symptoms.

4 rking memory than patients without prominent negative symptoms.

5 ited, 29 were classified as having prominent negative symptoms.

6 could be distinguished by NSS and prominent negative symptoms.

7 y resemble those of schizophrenia, including negative symptoms.

8 nd total NSS than patients without prominent negative symptoms.

9 ore illness domains: psychosis and cognitive/negative symptoms.

10 analysis revealed significant improvement of negative symptoms.

11 ther compounds in treating both positive and negative symptoms.

12 schizophrenia, with the potential to address negative symptoms.

13 MCCB scores were inversely correlated with negative symptoms.

14 ed periods of moderate to severe positive or negative symptoms.

15 lity for increasing severity of parent-rated negative symptoms.

16 associated with schizophrenia in particular negative symptoms.

17 istinguished EOS patients with predominantly negative symptoms.

18 mpal activity was positively correlated with negative symptoms.

19 e self-rated scales and 17% for parent-rated negative symptoms.

20 etween hippocampal activity and positive and negative symptoms.

21 logy of schizophrenia and, in particular, of negative symptoms.

22 lized medicine approach for the treatment of negative symptoms.

23 s were greatest among patients with elevated negative symptoms.

24 oms: the more the volume reduction, the more negative symptoms.

25 pirically developed and evaluated measure of negative symptoms.

26 related with the severity of a participant's negative symptoms.

27 lated with the severity of both positive and negative symptoms.

28 herwise different in patients with prominent negative symptoms.

29 whether these deficits were associated with negative symptoms.

30 esults of trials in patients with persistent negative symptoms.

31 nal alterations was unrelated to severity of negative symptoms.

32 ined sceptical as to its potential to reduce negative symptoms.

33 of auditory verbal hallucinations as well as negative symptoms.

34 everal of these abnormalities were linked to negative symptoms.

35 nia and the relationship between smoking and negative symptoms.

36 last week, compared with those with moderate negative symptoms.

37 choline receptor system for the treatment of negative symptoms.

38 her evaluation of behavioural activation for negative symptoms.

39 inic acetylcholine receptor availability and negative symptoms.

40 rmal activation correlated with positive and negative symptoms.

41 ts operant performance, a potential index of negative symptoms.

42 y in people with schizophrenia and prominent negative symptoms.

43 t and later maintenance of both positive and negative symptoms.

44 otype would be significantly associated with negative symptoms.

45 t is most pronounced in patients with severe negative symptoms.

46 oved efficacy in the treatment of persistent negative symptoms.

47 tween the presence of the risk haplotype and negative symptoms.

48 mediodorsal nucleus was associated with more negative symptoms.

49 variability of change in total, positive and negative symptoms.

50 ted with performance on processing speed and negative symptoms.

51 outcome via impaired cognition and increased negative symptoms.

52 separate pathways that involved or bypassed negative symptoms.

53 the latter accounting for 37% of variance in negative symptoms.

54 VST in CHR and an inverse relationship with negative symptoms.

55 riprazine in adult patients with predominant negative symptoms.

56 measured by the Scale for the Assessment of Negative Symptoms.

57 plications for the treatment of positive and negative symptoms.

58 Symptoms and the Scale for the Assessment of Negative Symptoms.

59 haloperidol and risperidone for reduction of negative symptoms.

60 er, a trend toward an effect was observed on negative symptoms.

61 tions were correlated with positive, but not negative, symptoms.

62 st shared environment for hallucinations and negative symptoms (17%-24%) and significant nonshared en

63 0.17 (-0.31 to -0.04) for brexpiprazole, for negative symptoms (32 015 participants) from -0.62 (-0.8

64 post hoc analysis of patients with moderate negative symptoms, 5 and 50 mg RG3487 vs placebo signifi

65 the MCCB; however, in patients with moderate negative symptoms, a post hoc analysis revealed signific

66 patients with schizophrenia and predominant negative symptoms across 66 sites worldwide.

67 edicted interpersonal and work skills, while negative symptoms affected interpersonal skills independ

68 t that long-lasting adaptations in LHb shape negative symptoms after drug taking.

69 r, as well as with attenuated improvement in negative symptoms after olanzapine treatment.

70 patients with schizophrenia with predominant negative symptoms and a high-degree of illness severity

71 A negative correlation between negative symptoms and activation in SMA and precentral g

72 equired concurrent remission of positive and negative symptoms and adequate social/vocational functio

73 ymorphisms associated with schizophrenia and negative symptoms and anxiety disorder but not with psyc

74 etic stimulation (rTMS) for the treatment of negative symptoms and call for adequately powered multic

75 nique pharmacological profile for addressing negative symptoms and cognitive deficits in schizophreni

76 lizumab, would improve residual positive and negative symptoms and cognitive deficits in schizophreni

77 ypically have minimal therapeutic effects on negative symptoms and cognitive deficits.

78 onstrated encouraging results on measures of negative symptoms and cognitive dysfunction in schizophr

79 et medical needs remain for the treatment of negative symptoms and cognitive dysfunction.

80 sode schizophrenia and its relationship with negative symptoms and cognitive functions.

81 s with schizophrenia frequently present with negative symptoms and cognitive impairments for which no

82 promising treatments for moderate to severe negative symptoms and cognitive impairments.

83 nia, depression, positive symptoms, anxiety, negative symptoms and disorganization.

84 Ketamine produced negative symptoms and disrupted delayed recall.

85 t in activities could lead to improvement in negative symptoms and function, but few trials have been

86 atistically significant efficacy in reducing negative symptoms and good tolerability in stable schizo

87 Higher levels of negative symptoms and hostility are specifically associa

88 tance of developing effective treatments for negative symptoms and hostility in order to improve the

89 Low levels of negative symptoms and hostility were significantly assoc

90 sychosis, poor premorbid functioning, stable negative symptoms and impaired social cognition and neur

91 d to a late stage characterized by long-term negative symptoms and impairments.

92 being highest for paranoia and parent-rated negative symptoms and lowest for hallucinations.

93 ssions to support activation for people with negative symptoms and mental health professional pessimi

94 etrieval accuracy negatively correlated with negative symptoms and no-retrieval accuracy negatively c

95 blunted ERN was associated with more severe negative symptoms and poorer real-world functioning, as

96 sponses for relevant stimuli help to explain negative symptoms and provide a unified explanation for

97 network hypothesis for medication-refractory negative symptoms and suggesting that network manipulati

98 everity from the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Po

99 re scores on the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Po

100 gions is associated with a greater number of negative symptoms and worse performance on tests of exec

101 Symptoms and the Scale for the Assessment of Negative Symptoms, and affective symptoms were assessed

102 arsed into three domains: positive symptoms, negative symptoms, and cognitive deficits.

103 matology characterized by positive symptoms, negative symptoms, and cognitive impairment.

104 s before clinic entry, baseline functioning, negative symptoms, and disorders of thought content.

105 amine the associations among EAP, cognition, negative symptoms, and functional outcome.

106 Symptoms and the Scale for the Assessment of Negative Symptoms, and volumetric measurements of the en

107 ammatory state, its association with primary negative symptoms, and whether there are significant dif

108 The effects on depressive and negative symptoms appeared more pronounced when minimum

109 phrenia, likely contributing to positive and negative symptoms as well as impaired cognition.

110 etiology characterized by both positive and negative symptoms, as well as cognitive deficits.

111 al circuits responsible for the positive and negative symptoms, as well as key new information about

112 dary outcomes were change in MCCB domain and negative symptom assessment (NSA) scores.

113 provement was seen at week 24 on the 16-item Negative Symptom Assessment Scale total score for ABT-12

114 otogenic action, producing both positive and negative symptoms associated with schizophrenia.

115 contribute to the emergence of positive and negative symptoms associated with schizophrenia.

116 hypofunction and the cognitive deficits and negative symptoms associated with this disease.

117 cognitive symptoms, but not the positive or negative symptoms, associated with schizophrenia.

118 n between DeltaBP(ND) in VST and severity of negative symptoms at baseline in the CHR group (r = -0.6

119 npsychotic disorder was associated with more negative symptoms at baseline.

120 itive dysfunction is commonly accompanied by negative symptoms (avolition, alogia, and affective flat

121 P < .001), cognition had a direct effect on negative symptoms (beta = -0.16, P < .001), and both cog

122 ion (beta = 0.26, P < .001) and experiential negative symptoms (beta = -0.75, P < .001) had direct ef

123 lly significant difference in improvement in negative symptoms between the two groups at day 21 (p =

124 ptoms, the Clinical Assessment Interview for Negative Symptoms (CAINS) was developed using an iterati

125 drome Scale (PANSS), Scale for Assessment of Negative Symptoms, Calgary Depression Scale for Schizoph

126 Correlates of psychosis, cognitive and negative symptoms can be found in white matter.

127 condary outcomes were change in positive and negative symptoms, categorical response to treatment, st

128 istically significant strong relationship of negative symptom change in response to functional connec

129 om Interview at 12 and 18 years of age), (2) negative symptoms (Community Assessment of Psychic Exper

130 the paranoid subtype or to have less severe negative symptoms compared with EOS patients.

131 .001), positive (CVR = 0.89, p < 0.001), and negative symptoms (CVR = 0.86, p = 0.001).

132 NC=0.04 vs dDC-NC=-0.49, p=0.008) but not on negative symptoms (dCC-NC=-0.09 vs dDC-NC=-0.31, p=0.41)

133 itional functional deficits in patients with negative symptoms, deficits which may explain the accomp

134 Negative symptoms demonstrated a negative association wi

135 enotypes and is associated with positive and negative symptom dimensions.

136 hrenia appears to be manifest as anxiety and negative symptoms during adolescence, a greater focus on

137 more severe in patients with high scores of negative symptoms during reward anticipation (r = -0.41;

138 Negative symptoms (e.g., anhedonia, amotivation, and exp

139 ria for either residual positive or residual negative symptoms entered a 16-week double-blind, parall

140 Patients with prominent negative symptoms exhibited significantly more motor coo

141 ched significance only in the alleviation of negative symptoms from an antipsychotic-free baseline (P

142 ANSS) outcomes (e.g., PANSS-Factor Score for Negative Symptoms [FSNS]) with Clinical Global Impressio

143 clinical features (i.e., positive symptoms, negative symptoms, functional deficits).

144 s significantly more efficacious in reducing negative symptoms (g=0.27).

145 neuropsychological functions, the prominent negative symptoms group still exhibited poorer motor coo

146 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainl

147 Patients with prominent negative symptoms had greater regional alterations in br

148 t twice as many patients with absent or mild negative symptoms had met a friend in the last week, com

149 A major barrier to developing treatments for negative symptoms has been measurement concerns with exi

150 Negative symptoms have previously been associated with r

151 ere are currently no licensed treatments for negative symptoms, highlighting the need to understand t

152 Apathy is a common negative symptom in schizophrenia.

153 BP1 risk haplotype and a lifetime history of negative symptoms in 181 Caucasian patients with schizop

154 We aimed to assess effects of D-serine on negative symptoms in at risk individuals.

155 ive striatum correlated with inattention and negative symptoms in CD, and with poorer working memory

156 with decreased goal-directed task effort and negative symptoms in consumers with schizophrenia was in

157 task and its relationship with positive and negative symptoms in early psychosis (EP, N = 88) and ch

158 ists produce schizophrenia-like positive and negative symptoms in healthy human subjects.

159 disorder and healthy control subjects and to negative symptoms in patients with schizophrenia.

160 ave robust efficacy in treating positive and negative symptoms in patients with schizophrenia.

161 BP1 genetic variation may be associated with negative symptoms in patients with schizophrenia.

162 differential benefit for either positive or negative symptoms in patients with treatment-resistant s

163 e was support for behavioural activation for negative symptoms in psychosis from some mental health w

164 tors, the difficulty in engaging people with negative symptoms in psychosocial treatments and service

165 are urgently searching for options to treat negative symptoms in schizophrenia because these symptom

166 s could underlie anhedonia in depression and negative symptoms in schizophrenia by disrupting learnin

167 The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST) was a

168 k effort indexed by pupillary responses, and negative symptoms in schizophrenia.

169 that may contribute to diminished effort and negative symptoms in schizophrenia.

170 ntal cortex for the treatment of predominant negative symptoms in schizophrenia.

171 rtial agonists for cognitive dysfunction and negative symptoms in schizophrenia.

172 one (n = 229) in a clinical study evaluating negative symptoms in schizophrenia.

173 vailability is altered in-vivo or related to negative symptoms in schizophrenia.

174 ties, in comparison with placebo in treating negative symptoms in stabilized patients with schizophre

175 onist, TC-5619, on cognitive dysfunction and negative symptoms in subjects with schizophrenia.

176 s associated with a significant reduction of negative symptoms in the 10-mg/d (mean [SE] reduction in

177 Antisaccade errors were correlated with negative symptoms in the patients.

178 mptoms performed worse than patients without negative symptoms in working memory functions but not ot

179 Negative symptoms, independent of structural volumes, pr

180 sure without reflux-symptom association (ie, negative symptom index and symptom association probabili

181 h absence of reflux-symptom association (ie, negative symptom index and symptom association probabili

182 In schizophrenia, the severity of negative symptoms is a key predictor of long-term disabi

183 altered effort allocation to the severity of negative symptoms is mixed.

184 py on prodromal states, acute schizophrenia, negative symptoms, loss of insight and relapse preventio

185 and paroxysmal positive symptoms as well as negative symptoms may be a consequence of varying degree

186 inic acetylcholine receptor availability and negative symptoms may explain the high rates of smoking

187 y matter observed in patients with prominent negative symptoms may provide unique insight into the ea

188 ailability was also strongly correlated with negative symptoms measured using the Positive and Negati

189 dity was demonstrated by linkages with other negative symptom measures, self-report scales of sociali

190 dence-based treatment for depression, to the negative symptoms observed in psychosis from the perspec

191 set P </= .05 threshold were associated with negative symptoms (odds ratio [OR] per SD increase in PR

192 n hedonic responses that are relevant to the negative symptoms of disorders such as schizophrenia.

193 is defined by core symptoms in two domains: negative symptoms of impairment in social and communicat

194 aceutical THC (with or without CBD) worsened negative symptoms of psychosis in a single study (SMD 0.

195 clude art therapy, are considered to improve negative symptoms of psychosis.

196 Negative symptoms of schizophrenia (NSS), related to hyp

197 ctively selected for persistent, predominant negative symptoms of schizophrenia (PNS), and minimal po

198 negativity, the Scale for the Assessment of Negative Symptoms of Schizophrenia (SANS) and the Brief

199 nAChR availability was associated with lower negative symptoms of schizophrenia and better performanc

200 Although predominant negative symptoms of schizophrenia can be severe enough

201 ignificant improvements in both positive and negative symptoms of schizophrenia compared to placebo (

202 tive effects across cognitive, positive, and negative symptoms of schizophrenia in animal models and

203 ds to a clinical impression in patients with negative symptoms of schizophrenia may help define the c

204 agonist prodrug decreased both positive and negative symptoms of schizophrenia raised hopes that glu

205 , and clinical studies have revealed reduced negative symptoms of schizophrenia with a dose of pregne

206 nderlying social withdrawal, one of the core negative symptoms of schizophrenia, are not well underst

207 onia in depression and both the positive and negative symptoms of schizophrenia, but it remains uncle

208 plus vitamin B12 supplementation can improve negative symptoms of schizophrenia, but treatment respon

209 ary outcomes included change in positive and negative symptoms of schizophrenia, categorical response

210 tal signaling appears blunted in MDD and the negative symptoms of schizophrenia, elevated in bipolar

211 More effective treatments are needed for negative symptoms of schizophrenia, which are typically

212 rically focused on reducing the positive and negative symptoms of schizophrenia, with recent increase

213 that changes in D3Rs may be involved in the negative symptoms of schizophrenia.

214 ynaptic plasticity and thereby might improve negative symptoms of schizophrenia.

215 s a treatment for the cognitive deficits and negative symptoms of schizophrenia.

216 ess striatal D2 receptors (D2R-OE) model the negative symptoms of schizophrenia.

217 ntipsychotic drugs for treating positive and negative symptoms of schizophrenia.

218 wal behaviors that may have relevance to the negative symptoms of schizophrenia.

219 nt in the pathology of both the positive and negative symptoms of schizophrenia.

220 s as potential new treatments for persistent negative symptoms of schizophrenia.

221 e improved overall symptoms and positive and negative symptoms of schizophrenia.

222 echanisms, for the treatment of positive and negative symptoms of schizophrenia.

223 cariprazine in the treatment of predominant negative symptoms of schizophrenia.

224 ly effective therapeutic option for treating negative symptoms or cognitive impairments.

225 Negative symptom outcomes and measures of parkinsonism a

226 ncluding total symptoms, depression/anxiety, negative symptoms, overall functioning, positive symptom

227 and Negative Syndrome Scale factor score for negative symptoms (PANSS-FSNS) analysed in a modified in

228 Patients with prominent negative symptoms performed worse than patients without

229 reliable measures of diagnosis, positive and negative symptoms, periods of untreated psychosis and pr

230 Patients had negative symptoms (Positive and Negative Syndrome Scale-

231 Depressive and negative symptoms (primary outcomes), overall symptoms,

232 x were associated with a greater severity of negative symptoms (r=0.42; P=0.017) and a lower level of

233 25) on sensitivity as well as of positive-to-negative symptom ratio (p=0.022) and antipsychotic medic

234 t of which have been shown to correlate with negative symptoms: reduced learning from rewards; blunte

235 rons to electrophysiological, cognitive, and negative-symptom-related behavioral phenotypes of schizo

236 des showed significantly greater severity of negative symptoms relative to consumers with mild defeat

237 , and core pathologies such as cognition and negative symptom remain unmet therapeutic challenges.

238 Disagreement was defined as a negative symptom report or no mention of a symptom in th

239 ontal cortex could affect hallucinations and negative symptoms, respectively.

240 (range, 24-168), Scale for the Assessment of Negative Symptoms (SANS) (range, 0-125), Montgomery-Asbe

241 effects, and the Scale for the Assessment of Negative Symptoms (SANS) and Brief Psychiatric Rating Sc

242 te of change" of Scale for the Assessment of Negative Symptoms (SANS) total scores and change in the

243 e (BPRS) and the Scale for the Assessment of Negative Symptoms (SANS), among other measures.

244 CSB composite score; Scale for Assessment of Negative Symptoms (SANS); Clinical Global Impression-Glo

245 luded a modified Scale for the Assessment of Negative Symptoms (SANS-18) and Positive and Negative Sy

246 essions Severity (CGI-S) scale and the Brief Negative Symptom Scale (BNSS).

247 eline in the total score on the Positive and Negative Symptom Scale (PANSS; range, 30 to 210; higher

248 Negative Syndrome Scale (PANSS) and a PANSS negative symptom scale that eliminated items that most o

249 al Global Impressions Scale (CGI), the Brief Negative Symptom Scale, the Brief Assessment of Cognitio

250 scores, the CGI severity item, and the Brief Negative Symptom Scale.

251 The key predictor of total positive and negative symptom score was greater in the primary psycho

252 ive symptoms, and positively correlated with negative symptom score.

253 ptoms in the 10-mg/d (mean [SE] reduction in negative symptoms score, -25% [2%]; P = .049) and 30-mg/

254 Negative symptom scores were significantly worse in the

255 lateral prefrontal cortex is associated with negative symptom severity and that correction of this br

256 signal abnormalities did not correlate with negative symptom severity in schizophrenia.

257 Higher negative symptom severity was associated with reduced ce

258 hat correction of this breakdown ameliorates negative symptom severity, supporting a novel network hy

259 ormance, functional capacity, or positive or negative symptom severity.

260 rd pairs; this underretrieval increased with negative symptom severity.

261 -cerebellum network directly corresponded to negative symptom severity.

262 etwork with connectivity that corresponds to negative symptom severity.

263 In addition, patients with negative symptoms showed impaired behavioural performanc

264 ity with TMS corresponded to amelioration of negative symptoms, showing a statistically significant s

265 Folate plus vitamin B12 improved negative symptoms significantly compared with placebo (g

266 itive symptoms (SMD 0.45) improved more than negative symptoms (SMD 0.35) and depression (SMD 0.27).

267 n difference: -0.25, 95% CI=-0.38 to -0.12), negative symptoms (standardized mean difference: -0.30,

268 vSAT task and the PANSS score driven by the negative symptom subscale.

269 nd working memory, as well as improvement in negative symptoms such as anhedonia and alogia.

270 ucinations, delusions and thought disorder), negative symptoms (such as social withdrawal, apathy and

271 Negative symptoms, such as amotivation and anhedonia, ar

272 network of regions predicted the severity of negative symptoms, such as impoverished speech and flatt

273 Analysis of primary outcomes (depressive and negative symptoms) suggests small, beneficial effects of

274 e symptoms (t = 0.249, df = 289, P = 0.803), negative symptoms (t = 0.151, df = 289, P = 0.879), or a

275 inic receptors, improved clinical ratings of negative symptoms that are generally resistant to treatm

276 Health's Consensus Development Conference on Negative Symptoms, the Clinical Assessment Interview for

277 strikingly and significantly correlated with negative symptoms: the more the volume reduction, the mo

278 uperior compared with sham rTMS in improving negative symptoms; this is in contrast to findings from

279 d inversely with the Scale for Assessment of Negative Symptoms total score and was lower in patients

280 econdary outcome measures, such as the PANSS negative symptom, total, and activation factor scores, t

281 Secondary outcomes included positive and negative symptoms, treatment recommendations by authors,

282 velopment and/or maintenance of positive and negative symptoms typically observed in schizophrenia.

283 At intake and follow-up, positive and negative symptoms were assessed with the Scale for the A

284 chizophrenia spectrum patients, positive and negative symptoms were associated with largely non-overl

285 specific data for patients with predominant negative symptoms were available.

286 osis and dimensionally measured positive and negative symptoms were elevated in deletion carriers.

287 and means of change in total, positive, and negative symptoms were extracted.

288 Negative symptoms were measured by the Scale for the Ass

289 consumers with mild defeatist attitudes and negative symptoms were significantly correlated with def

290 el for binary data showed that the prominent negative symptoms were stable over time.

291 he PANSS and the Scale for the Assessment of Negative Symptoms were used.

292 of olanzapine over haloperidol in improving negative symptoms when the PANSS and the Scale for the A

293 ate highly significant beneficial effects on negative symptoms when these compounds are added to both

294 al psychopathology, thought disturbance, and negative symptoms, whereas patients carrying the G allel

295 y symptoms, cognitive impairment, and severe negative symptoms, which impair functioning and require

296 ine induced a 35.7% (SD 17.8) improvement in negative symptoms, which was significant compared with p

297 Collectively, a subset of negative symptoms with a reduced willingness to expend c

298 prospective criteria for moderate to severe negative symptoms without marked positive, depressive, o

299 associated with significant improvements in negative symptoms without positive symptom worsening.

300 inuation was not associated with positive or negative symptom worsening.